Replies to post #87702 on Biotech Values

[mcbio]

Re: PYMX-SNY/NVS

The commercial benefit of having reversibility data would accrue not only to branded Lovenox, but also to any substitutable generic and vice-versa. Hence, if SNY or NVS sponsored a PMX-60056 program, they would be helping their competitor as much as they would be helping themselves.

But the reversibility could help either branded or generic Lovenox compete against the newer oral anti-coagulants, correct?